Evidence map›Paper›PMID 27554600›Full record

ArticleAngewandte Chemie (International ed. in English)2016

Development of Light-Activated CRISPR Using Guide RNAs with Photocleavable Protectors.

Piyush K Jain, Vyas Ramanan, Arnout G Schepers, Nisha S Dalvie, Apekshya Panda, Heather E Fleming, Sangeeta N Bhatia

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Light-Triggered CRISPR/Cas12a for Genomic Editing and Tumor Regression.Angewandte Chemie (International ed. in English) · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Optogenetic Tools for Regulating RNA Metabolism and Functions.Chembiochem : a European journal of chemical biology · 2024
    Review
  12. Article
  13. Article
  14. Engineered transcription-associated Cas9 targeting in eukaryotic cells.bioRxiv : the preprint server for biology · 2024
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Piyush K JainInstitute for Medical Engineering & Science, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.ORCID 0000-0001-7153-442X
Vyas RamananInstitute for Medical Engineering & Science, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Arnout G SchepersInstitute for Medical Engineering & Science, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.ORCID 0000-0001-9346-344X
Nisha S DalvieDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Apekshya PandaDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Heather E FlemingInstitute for Medical Engineering & Science, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Sangeeta N BhatiaInstitute for Medical Engineering & Science, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA. sbhatia@mit.edu.

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MATTHEW G. VANDER HEIDEN · 1985 to 2026
$93.9M
Stochastic gene expression in differentiation and developmentDP1CA174420 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI VAN OUDENAARDEN, ALEXANDER · 2012 to 2012
$832k
Howard Hughes Medical InstituteNCI NIH HHS DP1 CA174420NCI NIH HHS P30 CA014051
6 · The paper itself

Abstract

The ability to remotely trigger CRISPR/Cas9 activity would enable new strategies to study cellular events with greater precision and complexity. In this work, we have developed a method to photocage the activity of the guide RNA called "CRISPR-plus" (CRISPR-precise light-mediated unveiling of sgRNAs). The photoactivation capability of our CRISPR-plus method is compatible with the simultaneous targeting of multiple DNA sequences and supports numerous modifications that can enable guide RNA labeling for use in imaging and mechanistic investigations.

Indexed as

Base SequenceCRISPR-Cas SystemsGreen Fluorescent ProteinsHeLa CellsHumansLightNucleic Acid HybridizationPhotolysisRNA, Guide, CRISPR-Cas SystemsGreen Fluorescent ProteinsRNA, Guide, CRISPR-Cas SystemsCRISPRDNA cleavagegene technologynucleic acidsphotochemistry

Identifiers

PMID27554600
PMCPMC5864249

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.